In Vivo is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pervasis Therapeutics Inc.

Division of Takeda Pharmaceutical Co. Ltd.
www.pervasistx.com

Latest From Pervasis Therapeutics Inc.

Strong Market For Regenerative Medicine Deals Drives Value

Untapped market opportunities for treating and possibly curing underserved diseases have spurred an active deal-making environment in regenerative medicine, according to a new report from Datamonitor Healthcare.

Regenerative Medicine Deals

Shire faces RoI test under vision-loving new CEO

Shire Pharmaceuticals is known for its acquisitive buy-late, maximize-market strategy. Flemming Ornskov, the company's new CEO, plans to continue that approach, firstly by applying it to acquisitions in ophthalmology, an area in which he has specialized. However, with many recent acquisitions yet to mature to revenue-generation, and with big indication areas for Shire like ADHD at risk from generic and branded competition, the pressure is on the new CEO – even before he officially starts work.

Gastrointestinal

Reinventing Cell Therapy And Biomaterials

A profound redefinition of the role of many cell types and biomaterials in regenerative medicine is under way as researchers have moved away from the notion that cells introduced into the body will integrate and become functioning tissue.

Medical Device BioPharmaceutical

INTERVIEW: Acquired assets key to Shire's 'entrepreneurial' approach to regen medicine

The evolution of Shire's entrepreneurial regenerative medicine business continues with the appointment of Jeff Jonas as president of the division, which has been headquartered in San Diego, US since the $750 million acquisition of Advanced BioHealing and its bio-engineered skin substitute for diabetic foot ulcers Dermagraft in 2011 (scripintelligence.com, 18 May 2011).

Dermatology
See All

Company Information

  • Industry
  • Biotechnology
    • Gene Therapy, Cell Therapy
  • Medical Devices
  • Pharmaceuticals
  • Therapeutic Areas
  • Non-Specific
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Takeda Pharmaceutical Co. Ltd.
  • Senior Management
  • Helen Marie Nugent, PhD, VP, R&D
    Margaret O’Toole, Dir., Bus. Admin.
  • Contact Info
  • Pervasis Therapeutics Inc.
    Phone: (781) 522-6778
    1 Kendall Sq.
    Ste. B6101
    Cambridge, MA 02139-1663
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register